Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jmii.2020.05.014 http://scihub22266oqcxt.onion/10.1016/j.jmii.2020.05.014 32474026!7247474!32474026     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Microbiol+Immunol+Infect 2020 ; 53 (5): 674-675 Nephropedia Template TP {{tp|p=32474026|t=2020. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?|pdf=|usr=}}{{32474026}} gab.com Text Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial JO: J Microbiol Immunol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32474026 #FOAvip Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major global health challenge. Till date, no drug has been approved for the treatment of this infection. A number of medications have been proposed and there are ongoing clinical trials around the world to find a suitable treatment. A recent randomised control trial compared lopinavir/ritonavir with standard care among 199 patients with severe Covid-19 infection and concluded that there was no significant reduction in mortality rate with lopinavir/ritonavir. However, there are a few important lessons which may be learnt from the study apart from the statistical reduction in mortality rate. There was a numerical reduction in mortality rate, less intensive care unit stay and less complications in the lopinavir-ritonavir group. This article points out some of those important lessons with some suggestions for future clinical trials. Twit Text FOAVip Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial ????J Microbiol Immunol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32474026 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32474026 #FOAvip English Wikipedia <ref>{{Cite pmid|32474026}}</ref> Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? #MMPMID32474026 Owa AB; Owa OT J Microbiol Immunol Infect 2020[Oct]; 53 (5): 674-675 PMID32474026show ga Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major global health challenge. Till date, no drug has been approved for the treatment of this infection. A number of medications have been proposed and there are ongoing clinical trials around the world to find a suitable treatment. A recent randomised control trial compared lopinavir/ritonavir with standard care among 199 patients with severe Covid-19 infection and concluded that there was no significant reduction in mortality rate with lopinavir/ritonavir. However, there are a few important lessons which may be learnt from the study apart from the statistical reduction in mortality rate. There was a numerical reduction in mortality rate, less intensive care unit stay and less complications in the lopinavir-ritonavir group. This article points out some of those important lessons with some suggestions for future clinical trials. |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/mortality[MESH] |Drug Combinations[MESH] |Drug Resistance, Viral/physiology[MESH] |Humans[MESH] |Lopinavir/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/mortality[MESH] |Ritonavir/*therapeutic use[MESH]Lopinavir/ritonavir use in Covid-19 infection: is it completely non-be(epmc).pdf DeepDyve Pubget Overpricing